We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

120 hedge funds and large institutions have $343M invested in Entrada Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

47% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 32

28% more capital invested

Capital invested by funds: $269M → $343M (+$74.6M)

5% more funds holding

Funds holding: 114 → 120 (+6)

2.62% more ownership

Funds ownership: 68.47% → 71.09% (+2.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
120
Holders Change
+6
Holders Change %
+5.26%
% of All Funds
1.48%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
47
Reduced
32
Closed
13
Calls
$292K
Puts
–
Net Calls
+$292K
Net Calls Change
+$176K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.42M
2
LP
Longaeva Partners
Illinois
+$2.35M
3
TCM
TCG Crossover Management
California
+$2.28M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.28M
5
LCM
Lynx1 Capital Management
Puerto Rico
+$1.83M

Top Sellers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
-$1.45M
2
AG
Algert Global
California
-$1.32M
3
SFM
Sphera Funds Management
Israel
-$1.14M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$1.01M
5
Morgan Stanley
Morgan Stanley
New York
-$964K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
$2.29M +$2.05K +179 +0.1%
Morgan Stanley
27
Morgan Stanley
New York
$2.22M -$964K -84,125 -32%
N
28
Nuveen
North Carolina
$2.22M +$1.37M +119,232 +211%
NCM
29
Nantahala Capital Management
Connecticut
$2.01M +$1.83M +159,332 New
VFT
30
Vanguard Fiduciary Trust
Pennsylvania
$1.98M +$1.8M +156,861 New
XT
31
XTX Topco
Cayman Islands
$1.64M +$136K +11,894 +10%
RA
32
Royce & Associates
New York
$1.53M -$1.45M -126,302 -51%
MCM
33
Moore Capital Management
New York
$1.33M – – –
ACP
34
Acuta Capital Partners
California
$1.13M +$1.02M +89,358 New
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$1.1M -$1.01M -88,565 -50%
TI
36
Trexquant Investment
Connecticut
$1.04M -$442K -38,547 -32%
AQR Capital Management
37
AQR Capital Management
Connecticut
$1M +$610K +53,239 +203%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$998K +$139K +12,169 +18%
American Century Companies
39
American Century Companies
Missouri
$984K +$30.8K +2,689 +4%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$965K -$33.8K -2,948 -4%
QCM
41
Quantinno Capital Management
New York
$896K +$37.8K +3,301 +5%
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$892K +$162K +14,111 +25%
Ameriprise
43
Ameriprise
Minnesota
$887K -$167K -14,613 -17%
Marshall Wace
44
Marshall Wace
United Kingdom
$679K +$379K +33,107 +160%
TD Asset Management
45
TD Asset Management
Ontario, Canada
$676K +$181K +15,800 +42%
NFGH
46
Nan Fung Group Holdings
Hong Kong
$619K – – –
CF
47
Cantor Fitzgerald
New York
$593K -$115K -10,000 -18%
Two Sigma Investments
48
Two Sigma Investments
New York
$563K -$53.9K -4,700 -10%
Invesco
49
Invesco
Georgia
$529K +$10.2K +893 +2%
MAM
50
Martingale Asset Management
Massachusetts
$527K +$54K +4,710 +13%
1
2
3 4 5

TRDA Hedge Fund Activity: Q1 2026 in Review

120 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2026, worth a combined $343M — up 28% from $269M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TRDA positions and 13 closed out — a net gain of 7 holders — while 47 added to existing stakes and 32 trimmed.

The largest buyer was BlackRock, adding an estimated $2.42M. The largest seller was Royce & Associates, cutting an estimated $1.45M.

  • 120 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2026, up from 114 in Q4 2025.
  • Funds reported $343M of Entrada Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
  • 20 funds opened new Entrada Therapeutics positions in Q1 2026 and 13 closed out, a net change of +7 holders.
  • The largest Entrada Therapeutics buyer in Q1 2026 was BlackRock, an estimated $2.42M added.
  • The largest Entrada Therapeutics seller in Q1 2026 was Royce & Associates, an estimated $1.45M sold.

Based on aggregated 13F filings for Q1 2026.